Windtree Therapeutics
United States
unknown
unknown
Stage
About
Windtree Therapeutics is a cardiovascular and oncology drug development company (NASDAQ: WINT) whose lead candidate, istaroxime, is a Phase 2 molecule with FDA fast track designation being developed to treat acute heart failure and cardiogenic shock.
Explore Windtree Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.